P690 Monitoring ustekinumab levels in Inflammatory Bowel Disease in clinical practice: a window of opportunity
Year: 2024
Type: conference-abstract
Abstract: Background Ustekinumab (UST) is an effective drug in inflammatory bowel disease (IBD). Monitoring Ustekinumab trough levels in μg/mL (USTTL) can assist in the clinical management of these patients. Our objective was to analyze USTTL in patients with IBD, establish cutoff points associated with clinical response and remission, and analyze factors related to higher levels. Methods Observational, retrospective, and single-center study that included patients with IBD receiving UST treatment with at least one level determination. Before the initiation of UST (baseline) and prior to level extraction (periods 1 and 2), clinical and analytical data were collected as follow: Harvey-Bradshaw Index (HBI) in Crohn's disease (CD), partial Mayo Index (pMayo) in ulcerative colitis (UC), fecal calprotectin (FC) and C-reactive protein (CRP). Median and interquartile range (IQR) were used for quantitative variables, and percentage (%) for qualitative variables. Univariate and bivariate analyses were performed for response and clinical remission rates using ROC curves. Results A total of 125 patients with at least one USTTL determination were included. Figure 1 illustrates their baseline characteristics. In period 1, 62.4% of patients were on subcutaneous maintenance, and the median USTTL was 3.1 (1.6-5.3). 64% of patients responded to treatment, with higher USTTL than non-responders [4.1 (2.0-6.2) vs. 2.1 (1.0-4.5); p=0.006]. 42.5% achieved clinical remission with higher USTTL than those who did not achieve it [4.0 (2.3-5.7) vs. 2.5 (1.2-5.2) p=0.039]. Furthermore, patients on subcutaneous maintenance* had lower USTTL than those on subcutaneous and intravenous intensification [2.2 (1.3-3.5)* vs. 7.4 (5.1-10.8) and vs. 5.3 (3.3-12); p<0.001 and p=0.03, respectively). In the 46 patients with two determinations, statistically significant differences were found between period 1 and period 2 in USTTL [3.4 (1.9-6.4) vs. 7.2 (4.7-11.7) p<0.001], HBI [8 (4-9) vs. 4 (4-4.3); p<0.001], pMayo [4.5 (3-5) vs. 1 (1-3.3); p=0,042], FC [700 (180-2000) vs. 400 (108-1571); p=0.032), and corticosteroid use (41.3% vs. 26.1%; p=0.024). ROC curves were calculated for response and clinical remission in period 2. The USTTL cutoff points were 4.25 and 6.025μg/mL for response and clinical remission, respectively (figure 2). Conclusion Similar to previously published studies with anti-TNF, high levels of USTTL are associated with increased clinical remission and response. Patients undergoing UST treatment may benefit from a change in dosage to increase levels and achieve clinical remission. The cutoff point obtained for clinical remission was 6 μg/mL. Therefore, the determination of USTTL in daily clinical practice is a useful tool for the treatment of patients with IBD.
Source: Journal of Crohn s and Colitis
Institution: Hospital Universitario Virgen Macarena
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Keywords: ustekinumab, trough concentration
Open Access status: bronze
OpenAlex ID: W4391165249
